NTRK1 and neoplasm: Therefore, agents that reduce Bcl-2, Bcl-xL and/or Mcl1 expression combined with small molecule Trk inhibitors and agents that promote mitochondrial apoptosis, would be expected to kill TrkAIII expressing tumour cells.